Back to search
FDAFDA · Food and drugs·Recall number D-1437-2014

Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg/0.02 mg and 0.01 mg, 6 Cyclic dispensers X 28 tablets, Rx only Teva Pharmaceuticals, USA, Sellersville, PA. NDC 51285-114-58

Published July 23, 2014 · Recall initiated: June 17, 2014

Summary

FDA records drug Class III recall D-1437-2014, published July 23, 2014 and initiated June 17, 2014. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 984 blister packs; Lot: Lot 33805507A, Exp. date 11/14. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: out of specification impurity test results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide
Lot
Lot 33805507A, Exp. date 11/14
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mircette (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets 0.15 mg/0.02 mg and 0.01 mg, 6 Cyclic dispensers X 28 tablets, Rx only Teva Pharmaceuticals, USA, Sellersville, PA. NDC 51285-114-58 recalled?

Yes. FDA published recall D-1437-2014 on July 23, 2014. Reported hazard: Failed Impurities/Degradation Specifications: out of specification impurity test results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter